A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Acronyms LuDo
- 10 Sep 2018 Status changed from recruiting to completed.
- 03 Dec 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
- 23 Oct 2015 Accrual to date is 62% according to United Kingdom Clinical Research Network.